Children drinking non-cow milk little shorter than peers

Agencies
June 25, 2017

Jun 25: A new study suggests drinking non-cow milk- soy, almond or rice milks - is linked to shorter kids.cowmilk

The study, published in the American Journal of Clinical Nutrition, found that each daily cup of non-cow's milk consumed was associated with 0.4 centimeters (0.15 inches) lower height than average for a child's age.

"We found that children who are consuming non-cow's milk like rice, almond and soy milk tended to be a little bit shorter than children who consumed cow's milk," said Dr. Jonathon Maguire, the study's lead author and a pediatrician and researchers at St. Michael's Hospital in Toronto.

"For example, a 3-year-old child consuming three cups of non-cow's milk relative to cow's milk was on average 1.5 centimeters shorter."

That's over half an inch difference, which Maguire said is "not a tiny difference when you're 3 years old."

The study was a cross-section involving 5,034 healthy Canadian children ranging in age from two to six years old. The subjects were on average 38 months of age, with 51% being male, and were recruited from nine family and pediatric health-care practices from December 2008 to September 2015.

Of those participating, about five percent drank exclusively non-cow's milks, and about 84% drank only cow's milk; about eight percent drank both and about three precent drank neither.

Maguire said the most surprising finding was "that the amount children were shorter depended on how much they were consuming."

"It's not like if you're not consuming cow's milk, you're a little shorter," he said. "It's more like if you are consuming non-cow's milk, with each cup that a child consumes, that child on average appears to be a little bit smaller, a little shorter. That's a bit surprising."

Does it matter if a kid is half an inch shorter at the age of three? Does it correlate to height in adulthood?

"That's one remaining question. We don't know if the kids consuming non-cow's milk, maybe they catch up over time, or maybe they don't. Time's going to have to tell," he said.

"We do know in general as pediatricians that children who are on a certain percentile line in terms of height tend to stay on that line for the rest of their childhood and into adulthood."

The findings are sure to add fire to the ongoing debate about the benefits of cow's milk versus dairy alternatives.

Amy Joy Lanou, a professor of health and wellness at the University of North Carolina-Asheville who was not involved in the research, said she had several issues with the study, most notably why only milk consumption was considered.

"It's just odd to me why we wouldn't be looking at the overall diets of the children," Lanou said. "If they're making the claim that it's because it's the difference in the types of milk the kids are drinking, well, what else are they eating?"

Lanou, whose research has led her to believe that cow's milk is "not a necessary food," said she believes the study makes an improper leap by implying that taller means healthier.

"Taller children and heavier children are not necessarily healthier adults, or even healthier children," she said. "I think they're using height as a marker for health, and I'm not sure that's appropriate."

Connie Weaver, a professor of nutrition science at Purdue University who was also not involved in the study, said she found it interesting.

"This is the first study that I recall directly comparing cow milk with plant-based beverages for a physiological benefit," she wrote in an email. "We know that some of the plant beverages, almond especially, have lower protein contents so I have speculated that calcium absorption may be lower. This would suggest that cow's milk is superior."

However, she says, "A wrong message would be if people who do not consume cow's milk would decide to avoid the plant-based milks also."

The study suggests that one reason for the difference in height might be that plant-based milks do not stimulate insulin-like growth factor, or IGF, production as well as cow's milk does. Studies have found that adults with higher levels of certain IGFs have increased risks of reproductive cancers.

"Having less IGF may compromise height but that may lower risk of fracture -- and some cancers, too," Weaver said.

Overall, she would advise parents that "cow's milk may be the best option, but plant-based beverages provide many needed nutrients like protein, calcium, magnesium, potassium," which is far better than what most kids might prefer to drink.

Lanou would tell parents who are already giving plant-based milks to their children not to worry -- but to make sure their kids are getting enough protein from other sources throughout the day.

Maguire said he'd like to see soy, almond and rice milks more tightly regulated to bring the industry, in line with cow's milk.

"As a consumer and as a parent, you have to be pretty savvy when going to the grocery store to choose a non-cow's milk beverage that has similar nutritional value as cow's milk," he said. "Many of those beverages are marketed as being equivalent to cow's milk when they're not."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 27,2020

After admitting that the world may have a COVID-19 vaccine within one year or even a few months earlier, the World Health Organisation (WHO) on Friday said that UK-based AstraZeneca is leading the vaccine race while US-based pharmaceutical major Moderna is not far behind.

WHO Chief Scientist Soumya Swaminathan stated that the AstraZeneca's coronavirus vaccine candidate is the most advanced vaccine currently in terms of development.

"I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials," she told the media.

AstraZeneca's Covid-19 vaccine candidate developed by researchers from the Oxford University will likely provide protection against the disease for one year, the British drug maker's CEO told Belgian radio station Bel RTL this month.

The Oxford University last month announced the start of a Phase II/III UK trial of the vaccine, named AZD1222 (formerly known as ChAdOx1 nCoV-19), in about 10,000 adult volunteers. Other late-stage trials are due to begin in a number of countries.

Last week, Swaminathan had said that nearly 2 billion doses of the COVID-19 vaccine would be ready by the end of next year.

Addressing the media from Geneva, she said that "at the moment, we do not have a proven vaccine but if we are lucky, there will be one or two successful candidates before the end of this year" and 2 billion doses by the end of next year.

Scientists predict that the world may have a COVID-19 vaccine within one year or even a few months earlier, said the Director-General of the World Health Organization even as he underlined the importance of global cooperation to develop, manufacture and distribute the vaccines.

However, making the vaccine available and distributing it to all will be a challenge and will require political will, WHO chief Tedros Adhanom Ghebreyesus said on Thursday during a meeting with the European Parliament's Committee for Environment, Public Health and Food Safety.

One option would be to give the vaccine only to those who are most vulnerable to the virus.

There are currently over 100 COVID-19 vaccine candidates in various stages of development.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 19,2020

While coughing, fever and difficulty in breathing are common symptoms of COVID-19, a new case study has found that pink eye is also a reason to be tested for the disease.

The study, published in the Canadian Journal of Ophthalmology, determined that conjunctivitis and keratoconjunctivitis can also be primary symptoms of COVID-19.

The researchers noted that in March, a 29-year-old woman arrived at the Royal Alexandra Hospital's Eye Institute of Alberta with a severe case of conjunctivitis and minimal respiratory symptoms.

After the patient had undergone several days of treatment with little improvement -- and after it had been determined that the woman had recently returned home from Asia -- a resident ordered a COVID-19 test.

The test came back positive, according to the researchers.

"What is interesting in this case, and perhaps very different to how it had been recognised at that specific time, was that the main presentation of the illness was not a respiratory symptom. It was the eye," said Carlos Solarte, an assistant professor at the University of Alberta in Canada.

"There was no fever and no cough, so we weren't led to suspect COVID-19 at the beginning. We didn't know it could present primarily with the eye and not with the lungs," Solarte said.

Academic studies at the outset of the pandemic identified conjunctivitis as a secondary symptoms in about 10 to 15 per cent of COVID-19 cases, he said.

Since then, scientists have gained greater knowledge of how the virus can transmit through and affect the body's mucous membrane system, of which the conjunctiva -- the clear, thin membrane that covers the front surface of the eye -- is an extension.

While the finding provides important new health information for the public, it also makes eye exams more complicated for ophthalmologists and staff, the researchers noted.

"The patient in this case eventually recovered well without any issues. But several of the residents and staff who were in close contact with the patient had to be under quarantine," said Solarte.

"Fortunately, none who were involved in her care also tested positive," he said.

Patients coming into an eye clinic with conjunctivitis and keratoconjunctivitis are now treated as potential cases of COVID-19 and extra precautions are taken by staff, according to the researchers.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
February 4,2020

Despite tremendous advances in treatment of congenital heart disease (CHD), a new global study shows that the chances for a child to survive a CHD diagnosis is significantly less in low-income countries.

The research revealed that nearly 12 million people are currently living with CHD globally, 18.7 per cent more than in 1990.

The findings, published in The Lancet, is drawn from the first comprehensive study of congenital heart disease across 195 countries, prepared using data from the Global Burden of Diseases, Injuries and Risk Factors Study 2017 (GBD).

"Previous congenital heart estimates came from few data sources, were geographically narrow and did not evaluate CHD throughout the life course," said the study authors from Children's National Hospital in the US.

This is the first time the GBD study data was used along with all available data sources and previous publications - making it the most comprehensive study on the congenital heart disease burden to date.

The study found a 34.5 per cent decline in deaths from congenital disease between 1990 to 2017. Nearly 70 per cent of deaths caused by CHD in 2017 (180,624) were in infants less than one year old.

Most CHD deaths occurred in countries within the low and low-middle socio-demographic index (SDI) quintiles.

Mortality rates get lower as a country's Socio-demographic Index (SDI) rises, the study said.

According to the researchers, birth prevalence of CHD was not related to a country's socio-demographic status, but overall prevalence was much lower in the poorest countries of the world.

This is because children in these countries do not have access to life saving surgical services, they added.

"In high income countries like the United States, we diagnose some heart conditions prenatally during the 20-week ultrasound," said Gerard Martin from Children's National Hospital who contributed to the study.

"For children born in middle- and low-income countries, these data draw stark attention to what we as cardiologists already knew from our own work in these countries -- the lack of diagnostic and treatment tools leads to lower survival rates for children born with CHD," said researcher Craig Sable.

"The UN has prioritised reduction of premature deaths from heart disease, but to meet the target of 'ending preventable deaths of newborns and children under 5 years of age,' health policy makers will need to develop specific accountability measures that address barriers and improve access to care and treatment," the authors wrote.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.